The Pharmacodynamics of Doripenem Between 4-hour and 1-hour Infusion in Patients With Ventilator-associated Pneumonia
NCT01467648 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 12
Last updated 2011-11-09
Summary
This is prospective and randomized study to assess the pharmacodynamics (t\>MIC) of 0.5 g every 8 h of doripenem in patients with VAP following administration by a 4 h infusion or 1 h infusion.
Clinical and laboratory data such as Age,Sex, Body weight, Electrolyte, Vital signs, APACHE II score, BUN, Cr, Blood culture will be collected.
Twelve patients will be enrolled in this study. After completion of the doripenem therapy for 3 days in this study, all patients will receive other sensitive antibiotics to eradicate their bacterial infections.
Doripenem pharmacokinetic study will be carried out during the doripenem therapy. Blood samples (approximately 2 ml) in group " 0.5 g of doripenem with 4 h infusion every 8 h regimen" will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 8 h after 7th dose of doripenem.
Blood samples (approximately 2 ml) in group " 0.5 g of doripenem with 1 h infusion every 8 h regimen" will be obtained by direct venepuncture at the following time: 1, 1.5, 2, 4, 5, 6, 7 and 8 h after 7th dose of doripenem.
The doripenem assays by method of Ikeda K et al. (J Chromatogr B, 2008) will be performed.
Concentration of doripenem in plasma will be simulated in Monte Carlo technique (Computer model) to get PK/PD index (40%T\>MIC) and reported to % PTA (Probability Target Attainment) and %CFR (Cumulative Faction Response)
Conditions
- Ventilator-Associated Pneumonia
Interventions
- DRUG
-
Doripenem
(i) 0.5 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 1 h every 8 h. Blood samples (approximately 2 ml)will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 8 h after 7th dose of doripenem.
- DRUG
-
Doripenem
(ii) 0.5 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 1 h every 8 h. Blood samples (approximately 2 ml) will be obtained by direct venepuncture at the following time: 1, 1.5, 2, 4, 5, 6, 7 and 8 h after 7th dose of doripenem.
Sponsors & Collaborators
-
Prince of Songkla University
collaborator OTHER -
Sutep Jaruratanasirikul
lead OTHER
Principal Investigators
-
Sutep Jaruratanasirikul, MD · Prince of Songkha
Study Design
- Allocation
- RANDOMIZED
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-10-31
- Primary Completion
- 2011-10-31
- Completion
- 2011-10-31
Countries
- Thailand
Study Locations
More Related Trials
-
Five Versus Seven Day Antibiotic Course for the Treatment of Pneumonia in the Intensive Care Unit
NCT01554657 ·Status: COMPLETED ·Phase: NA
-
Nebulized Amikacin Versus Intravenous Amikacin in the Treatment of Nosocomial Pneumonia
NCT02728518 ·Status: COMPLETED ·Phase: NA
-
Oral Care Interventions and Ventilator Associated Pneumonia in Critically Ill Children
NCT01083407 ·Status: COMPLETED ·Phase: PHASE1
-
Study Comparing Inhaled Amikacin Versus Placebo to Prevent Ventilator Associated Pneumonia
NCT03149640 ·Status: COMPLETED ·Phase: PHASE3
-
Immediate Versus Substantiated Antibiotic Therapy in Suspected Non-Severe Ventilator-Associated Pneumonia
NCT06743529 ·Status: RECRUITING ·Phase: NA
-
Impact of Oral Care on Ventilator Associated Pneumonia
NCT07287566 ·Status: COMPLETED ·Phase: NA
-
Antimicrobial Stewardship For Ventilator Associated Pneumonia in Intensive Care
NCT05124977 ·Status: RECRUITING ·Phase: NA
-
Effect of Additional Nebulized Amikacin in Ventilator-Associated Pneumonia Caused by Gram Negative Bacteria
NCT02574130 ·Status: COMPLETED ·Phase: NA
-
Inhaled Polymyxin E to Prevent VAP
NCT06819462 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Modular Prevention Bundle for Non-ventilator-associated Hospital-acquired Pneumonia (nvHAP)
NCT03361085 ·Status: TERMINATED ·Phase: NA
-
Pharmacokinetics of Nebulized Amikacin in Patients With Pneumonia Undergoing Mechanical Ventilation
NCT00861315 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Chlorhexidine Gluconate for Prevention of Ventilator Associated Pneumonia in Children.
NCT01883596 ·Status: UNKNOWN ·Phase: PHASE4
-
Impact of the Duration of Antibiotics on Clinical Events in Patients With Pseudomonas Aeruginosa Ventilator-associated Pneumonia (iDIAPASON)
NCT02634411 ·Status: COMPLETED ·Phase: NA
-
Pulmonary Diffusion of Antibiotics in Patients Admitted for ARDS Following SARS-CoV-2 Pneumonia
NCT05464680 ·Status: COMPLETED ·Phase: NA
-
Aerosolized Antibiotics in the Treatment of Ventilator Associated Pneumonia
NCT02478710 ·Status: TERMINATED ·Phase: PHASE4
-
Hospital-acquired Pneumonia Prevention: Intervention, Evaluation & Research
NCT04915898 ·Status: COMPLETED ·Phase: NA
-
The Effect of Colistin Inhalation on Ventilator Associated Pneumonia
NCT03622450 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
7-days Versus 14 Days of Antibiotics Therapy for Ventilator Associated Pneumonia
NCT03477292 ·Status: COMPLETED ·Phase: NA
-
Chlorhexidine Gluconate Oral Care for Adults Experiencing Trauma
NCT01382446 ·Status: COMPLETED ·Phase: NA
-
Prehospital Ventilator-Associated Pneumonia Prevention Trial
NCT01902446 ·Status: COMPLETED
-
Microbial Etiology of Ventilator-associated Pneumonia in COVID-19 Infected Patients
NCT04344509 ·Status: UNKNOWN
-
Early Antibiotics After Aspiration in ICU Patients
NCT05079620 ·Status: TERMINATED ·Phase: PHASE4
-
PK/PD and Clinial Outcomes of Beta-lactams in ICU Patients
NCT03858387 ·Status: UNKNOWN
-
Methods of Chlorhexidine Cleansing to Prevent Ventilator-Associated Pneumonia (VAP)
NCT02077920 ·Status: COMPLETED ·Phase: PHASE2
-
Oro-nasal Decontamination to Prevent Ventilator-associated Pneumonia
NCT05895773 ·Status: COMPLETED ·Phase: PHASE2/PHASE3